Cargando…
Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now?
The incidence of prostate cancer (PC) has risen annually. PC mortality is explained by the metastatic disease (mPC). There is an intermediate scenario in which patients have non-mPC but have initiated a metastatic cascade through epithelial–mesenchymal transition. There is indeed a need for more and...
Autores principales: | San Francisco, Ignacio F., Rojas, Pablo A., Bravo, Juan C., Díaz, Jorge, Ebel, Luis, Urrutia, Sebastián, Prieto, Benjamín, Cerda-Infante, Javier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10420177/ https://www.ncbi.nlm.nih.gov/pubmed/37569883 http://dx.doi.org/10.3390/ijms241512508 |
Ejemplares similares
-
Where are we now and where are we headed?
por: Langan, Ewan A.
Publicado: (2023) -
Where are we now?
Publicado: (1977) -
AI in medicine: Where are we now and where are we going?
por: Shandhi, Md Mobashir Hasan, et al.
Publicado: (2022) -
Intrahepatic Cholangiocarcinoma—Where Are We Now and Where Are We Going to?
por: Wasilewicz, Michał P., et al.
Publicado: (2023) -
Ventilator-associated tracheobronchitis: where are we
now?
por: Nseir, Saad, et al.
Publicado: (2014)